It is estimated that migraine, the most common neurological disorder, affects 23 per cent of women and 10 per cent of men in Canada. More than three million Canadians, close to 17 per cent have been diagnosed with migraine. There is wide variation in the severity and frequency of attacks between patients and within an individual over time. It is therefore important to find a medication that can take effect in as early as 30 minutes in order to relieve the pain and associated symptoms, especially nausea. There are two types of migraines.
Auras are neurological symptoms that are typically visual.
Sufferers may see flashing lights or zigzag patterns or may have other neurological complaints. These symptoms may occur over a variable period of time before an attack. The majority of migraine sufferers do not experience an aura prior to their migraine episodes. Maxalt is indicated for treatment of migraines with or without aura. Maxalt has been evaluated in worldwide studies with more than 3,500 patients and has been approved in many countries, such as the United States, United Kingdom, Netherlands and Mexico.